CA Patent

CA2813478A1 — Phase change inks comprising crystalline amides

Assigned to Xerox Corp · Expires 2013-10-26 · 13y expired

What this patent protects

A phase change ink composition suitable for high speed ink jet printing, including printing on coated paper substrates. In embodiments, the phase change ink composition comprises both a crystalline compound and an amorphous compound, and optionally, a colorant, which provides for…

USPTO Abstract

A phase change ink composition suitable for high speed ink jet printing, including printing on coated paper substrates. In embodiments, the phase change ink composition comprises both a crystalline compound and an amorphous compound, and optionally, a colorant, which provides for a robust ink. The crystalline compound is an amide and the amorphous compound is an ester of tartaric acid.

Drugs covered by this patent

Patent Metadata

Patent number
CA2813478A1
Jurisdiction
CA
Classification
—
Expires
2013-10-26
Drug substance claim
No
Drug product claim
No
Assignee
Xerox Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.